ImmuPharma (LON:IMM) Trading Down 14.6% – Time to Sell?

Shares of ImmuPharma plc (LON:IMMGet Free Report) fell 14.6% during mid-day trading on Tuesday . The company traded as low as GBX 3.20 ($0.04) and last traded at GBX 3.20 ($0.04). 13,200,714 shares changed hands during mid-day trading, a decline of 53% from the average session volume of 28,314,303 shares. The stock had previously closed at GBX 3.75 ($0.05).

ImmuPharma Price Performance

The firm’s fifty day moving average price is GBX 1.48 and its 200-day moving average price is GBX 1.66. The company has a market cap of £13.33 million, a price-to-earnings ratio of -320.00 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Stories

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.